352 related articles for article (PubMed ID: 33028119)
1. The role of synaptic biomarkers in the spectrum of neurodegenerative diseases.
Mazzucchi S; Palermo G; Campese N; Galgani A; Della Vecchia A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F
Expert Rev Proteomics; 2020; 17(7-8):543-559. PubMed ID: 33028119
[TBL] [Abstract][Full Text] [Related]
2. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.
Clarke MTM; Brinkmalm A; Foiani MS; Woollacott IOC; Heller C; Heslegrave A; Keshavan A; Fox NC; Schott JM; Warren JD; Blennow K; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2019 Dec; 11(1):105. PubMed ID: 31847891
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
[TBL] [Abstract][Full Text] [Related]
4. Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease.
Tible M; Sandelius Å; Höglund K; Brinkmalm A; Cognat E; Dumurgier J; Zetterberg H; Hugon J; Paquet C; Blennow K
Neurology; 2020 Aug; 95(8):e953-e961. PubMed ID: 32586895
[TBL] [Abstract][Full Text] [Related]
5. Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia.
Willemse EAJ; Sieben A; Somers C; Vermeiren Y; De Roeck N; Timmers M; Van Broeckhoven C; De Vil B; Cras P; De Deyn PP; Martin JJ; Teunissen CE; Engelborghs S; Bjerke M
Neurobiol Aging; 2021 Dec; 108():99-109. PubMed ID: 34551375
[TBL] [Abstract][Full Text] [Related]
6. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
[TBL] [Abstract][Full Text] [Related]
7. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias.
Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Polischi B; Capellari S; Parchi P
Alzheimers Res Ther; 2023 Sep; 15(1):150. PubMed ID: 37684653
[TBL] [Abstract][Full Text] [Related]
9. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.
Schindler SE; Li Y; Todd KW; Herries EM; Henson RL; Gray JD; Wang G; Graham DL; Shaw LM; Trojanowski JQ; Hassenstab JJ; Benzinger TLS; Cruchaga C; Jucker M; Levin J; Chhatwal JP; Noble JM; Ringman JM; Graff-Radford NR; Holtzman DM; Ladenson JH; Morris JC; Bateman RJ; Xiong C; Fagan AM;
Alzheimers Dement; 2019 May; 15(5):655-665. PubMed ID: 30846386
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.
Portelius E; Olsson B; Höglund K; Cullen NC; Kvartsberg H; Andreasson U; Zetterberg H; Sandelius Å; Shaw LM; Lee VMY; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk DA; McCluskey L; Elman L; McBride J; Toledo JB; Trojanowski JQ; Blennow K
Acta Neuropathol; 2018 Sep; 136(3):363-376. PubMed ID: 29700597
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
Kvartsberg H; Duits FH; Ingelsson M; Andreasen N; Öhrfelt A; Andersson K; Brinkmalm G; Lannfelt L; Minthon L; Hansson O; Andreasson U; Teunissen CE; Scheltens P; Van der Flier WM; Zetterberg H; Portelius E; Blennow K
Alzheimers Dement; 2015 Oct; 11(10):1180-90. PubMed ID: 25533203
[TBL] [Abstract][Full Text] [Related]
12. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
Antonell A; Tort-Merino A; Ríos J; Balasa M; Borrego-Écija S; Auge JM; Muñoz-García C; Bosch B; Falgàs N; Rami L; Ramos-Campoy O; Blennow K; Zetterberg H; Molinuevo JL; Lladó A; Sánchez-Valle R
Alzheimers Dement; 2020 Feb; 16(2):262-272. PubMed ID: 31668967
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
14. Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons.
Nazir FH; Becker B; Brinkmalm A; Höglund K; Sandelius Å; Bergström P; Satir TM; Öhrfelt A; Blennow K; Agholme L; Zetterberg H
Neurochem Int; 2018 Dec; 121():38-49. PubMed ID: 30342961
[TBL] [Abstract][Full Text] [Related]
15. Neurogranin in Alzheimer's disease and ageing: A human post-mortem study.
Saunders T; Gunn C; Blennow K; Kvartsberg H; Zetterberg H; Shenkin SD; Cox SR; Deary IJ; Smith C; King D; Spires-Jones T
Neurobiol Dis; 2023 Feb; 177():105991. PubMed ID: 36623608
[TBL] [Abstract][Full Text] [Related]
16. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.
Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Nisticò R; Floris R; Garaci F; Hampel H;
J Alzheimers Dis; 2017; 59(4):1327-1334. PubMed ID: 28731449
[TBL] [Abstract][Full Text] [Related]
18. A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease.
Öhrfelt A; Brinkmalm A; Dumurgier J; Zetterberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
Neuroscience; 2019 Nov; 420():136-144. PubMed ID: 30528858
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer's Disease from Other Neurological Disorders.
Piccoli T; Blandino V; Maniscalco L; Matranga D; Graziano F; Guajana F; Agnello L; Lo Sasso B; Gambino CM; Giglio RV; La Bella V; Ciaccio M; Colletti T
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142742
[TBL] [Abstract][Full Text] [Related]
20. Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Dulewicz M; Kulczyńska-Przybik A; Mroczko B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
